SS
MCRB icon

Steve Schonfeld’s Seres Therapeutics MCRB Stock Holding History

Steve Schonfeld’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-29,097
Closed -$433K – 2476
2025
Q4 		$433K Buy
29,097
+155
+0.5% +$2.7K ﹤0.01% 1446
2025
Q3 		$557K Buy
+28,942
New +$462K ﹤0.01% 1643
2025
Q2 		– Sell
-2,565
Closed -$35.9K – 2334
2025
Q1 		$35.9K Sell
2,565
-2,470
-49% -$38.7K ﹤0.01% 2083
2024
Q4 		$83.7K Sell
5,035
-16,660
-77% -$271K ﹤0.01% 1849
2024
Q3 		$411K Buy
21,695
+18,690
+622% +$379K ﹤0.01% 1524
2024
Q2 		$43.5K Buy
+3,005
New +$50.1K ﹤0.01% 1950
2023
Q3 		– Sell
-11,113
Closed -$1.06M – 2081
2023
Q2 		$1.06M Buy
+11,113
New +$1.21M 0.01% 944
2021
Q3 		– Sell
-5,330
Closed -$2.54M – 2339
2021
Q2 		$2.54M Buy
+5,330
New +$2.25M 0.03% 644
2021
Q1 		– Sell
-723
Closed -$355K – 2006
2020
Q4 		$355K Buy
723
+123
+21% +$72K ﹤0.01% 1150
2020
Q3 		$339K Buy
+600
New +$200K 0.01% 1053

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Vontobel Holding
Vontobel Holding Zurich, Switzerland $31.4B AUM 31.97% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Steve Schonfeld's MCRB Position: Q1 2026 in Review

Steve Schonfeld sold out of Seres Therapeutics (MCRB) in Q1 2026, closing a stake of 29,097 shares — an estimated $433K sold.

Steve Schonfeld first reported a position in MCRB in Q3 2020 and held it in 10 quarters. The position peaked at $2.54M in Q2 2021. 33 funds tracked by Wall St. Rank hold MCRB as of Q1 2026.

  • Steve Schonfeld reported no remaining Seres Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Steve Schonfeld sold 29,097 Seres Therapeutics shares in Q1 2026, an estimated $433K.
  • Steve Schonfeld first reported a position in Seres Therapeutics in Q3 2020 and held it in 10 quarters.
  • Steve Schonfeld's Seres Therapeutics position peaked at $2.54M in Q2 2021.
  • 33 funds tracked by Wall St. Rank held Seres Therapeutics as of Q1 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.